Immunotherapeutic approach to the treatment and prevention of obesity

Tatsuhiko Azegami; Hiroshi Itoh

doi:10.1007/978-3-030-53370-0_22

Immunotherapeutic approach to the treatment and prevention of obesity

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Clinical availability of anti-obesity drugs is limited, and their inadequate effectiveness and safety concerns sometimes discourage widespread use. A therapeutic vaccine has the potential to be an attractive tool for preventing and treating obesity, because of the possibility of prolonged therapeutic effect and low frequency of administration. Experimental investigations have shown that vaccines targeting endogenous molecules that promote obesity could be a viable alternative. Recent novelties in drug-delivery systems and biotechnology will support further progress in vaccine development. This chapter provides an overview of recent advances in the area.

Original language	English
Title of host publication	Obesity and Diabetes
Subtitle of host publication	Scientific Advances and Best Practice
Publisher	Springer International Publishing
Pages	297-302
Number of pages	6
ISBN (Electronic)	9783030533700
ISBN (Print)	9783030533694
DOIs	https://doi.org/10.1007/978-3-030-53370-0_22
Publication status	Published - 2020 Dec 14

Keywords

Adenovirus 36
Adipocyte
Ghrelin
Glucose-dependent Insulinotropic Polypeptide
Immunotherapy
Somatostatin
Vaccine

ASJC Scopus subject areas

Medicine(all)
Biochemistry, Genetics and Molecular Biology(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-3-030-53370-0_22

Cite this

@inbook{bb066fcc6aa14f47ad1572a5091d740d,

title = "Immunotherapeutic approach to the treatment and prevention of obesity",

abstract = "Clinical availability of anti-obesity drugs is limited, and their inadequate effectiveness and safety concerns sometimes discourage widespread use. A therapeutic vaccine has the potential to be an attractive tool for preventing and treating obesity, because of the possibility of prolonged therapeutic effect and low frequency of administration. Experimental investigations have shown that vaccines targeting endogenous molecules that promote obesity could be a viable alternative. Recent novelties in drug-delivery systems and biotechnology will support further progress in vaccine development. This chapter provides an overview of recent advances in the area.",

keywords = "Adenovirus 36, Adipocyte, Ghrelin, Glucose-dependent Insulinotropic Polypeptide, Immunotherapy, Somatostatin, Vaccine",

author = "Tatsuhiko Azegami and Hiroshi Itoh",

note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2020.",

year = "2020",

month = dec,

day = "14",

doi = "10.1007/978-3-030-53370-0_22",

language = "English",

isbn = "9783030533694",

pages = "297--302",

booktitle = "Obesity and Diabetes",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Immunotherapeutic approach to the treatment and prevention of obesity

AU - Azegami, Tatsuhiko

AU - Itoh, Hiroshi

N1 - Publisher Copyright: © Springer Nature Switzerland AG 2020.

PY - 2020/12/14

Y1 - 2020/12/14

N2 - Clinical availability of anti-obesity drugs is limited, and their inadequate effectiveness and safety concerns sometimes discourage widespread use. A therapeutic vaccine has the potential to be an attractive tool for preventing and treating obesity, because of the possibility of prolonged therapeutic effect and low frequency of administration. Experimental investigations have shown that vaccines targeting endogenous molecules that promote obesity could be a viable alternative. Recent novelties in drug-delivery systems and biotechnology will support further progress in vaccine development. This chapter provides an overview of recent advances in the area.

AB - Clinical availability of anti-obesity drugs is limited, and their inadequate effectiveness and safety concerns sometimes discourage widespread use. A therapeutic vaccine has the potential to be an attractive tool for preventing and treating obesity, because of the possibility of prolonged therapeutic effect and low frequency of administration. Experimental investigations have shown that vaccines targeting endogenous molecules that promote obesity could be a viable alternative. Recent novelties in drug-delivery systems and biotechnology will support further progress in vaccine development. This chapter provides an overview of recent advances in the area.

KW - Adenovirus 36

KW - Adipocyte

KW - Ghrelin

KW - Glucose-dependent Insulinotropic Polypeptide

KW - Immunotherapy

KW - Somatostatin

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85150973075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85150973075&partnerID=8YFLogxK

U2 - 10.1007/978-3-030-53370-0_22

DO - 10.1007/978-3-030-53370-0_22

M3 - Chapter

AN - SCOPUS:85150973075

SN - 9783030533694

SP - 297

EP - 302

BT - Obesity and Diabetes

PB - Springer International Publishing

ER -

Immunotherapeutic approach to the treatment and prevention of obesity

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this